Business context and reporting period
This is an unaudited Form 10-Q for Galena Biopharma, Inc. for the three months ended March 31, 2017. The request metadata names SELLAS Life Sciences Group, Inc., but the supplied filing identifies Galena Biopharma as the registrant.
Galena was a clinical-stage biopharmaceutical company developing GALE-401 and cancer immunotherapy candidates NeuVax, GALE-301 and GALE-302. It had sold its commercial-product rights in 2015; no revenue was reported for the quarter. The company was reviewing strategic alternatives, including continuing independently, a sale, merger, or asset licensing or disposition.
Financial results and liquidity
| Metric | Q1 2017 | Q1 2016 / prior balance date |
|---|---|---|
| Revenue | None reported | None reported |
| R&D expense | $2.362 million | $5.443 million |
| G&A expense | $2.726 million | $3.525 million |
| Operating loss | $5.088 million | $8.968 million |
| Net loss | $11.718 million | $16.493 million |
| Net loss per share | $0.45 | $1.84 |
| Operating cash used | $10.404 million | $13.216 million |
| Cash and cash equivalents | $27.640 million | $18.083 million at Dec. 31, 2016 |
| Restricted cash | $13.590 million | $18.022 million at Dec. 31, 2016 |
| Total assets | $70.332 million | $65.811 million at Dec. 31, 2016 |
| Total liabilities | $43.138 million | $37.154 million at Dec. 31, 2016 |
Gross margin is not applicable to the reported quarter because the company reported no revenue. Cash increased by $9.557 million, chiefly from $15.524 million net proceeds from a February stock-and-warrant offering and repayment of $4.450 million of debenture principal in shares; operating cash use partly offset these sources. Continuing-operations operating cash use was $5.400 million, while discontinued operations used $5.004 million.
At March 31, 2017, the debenture’s outstanding principal was $13.172 million, with $12.597 million recorded as current debt after discounts and issuance costs. The debt bears 9% annual interest, matures in November 2018, is secured by company assets, and permits monthly holder redemptions. The company’s stock-payment option is subject to conditions and waivers. Management said unrestricted cash should fund operations for at least twelve months from issuance of the financial statements, but also said additional capital would be needed absent a strategic transaction.
Material changes versus the prior comparable period
- Net loss narrowed by $4.775 million, although the comparison was significantly affected by noncash warrant remeasurement: a $3.892 million gain in Q1 2017 versus a $3.873 million loss in Q1 2016.
- Operating expenses fell, primarily because the Phase 3 PRESENT trial had been discontinued in 2016; R&D expense declined 57% and G&A declined 23%.
- Discontinued-operations loss increased to $9.436 million from $3.391 million, including a $7.5 million accrued civil settlement payment relating to the Abstral investigation.
- Cash rose following the February equity-and-warrant offering. Common shares issued increased from 15.2 million at year-end to 37.2 million at March 31; the offering also issued 17 million warrants with a $1.10 exercise price.
Outlook, management commentary, risks and unusual items
- Strategic review and funding: There was no timetable or assurance of a transaction. The company limited spending to preserve liquidity, but warned that it would need more capital to continue development absent a strategic transaction. Its LPC and at-the-market equity facilities were unavailable while it was ineligible to use Form S-3, which management said would not be available before April 2018 at the earliest.
- Clinical programs: GALE-401 had completed Phase 2; management said it could move toward Phase 3 subject to manufacturing and preparation work, with a decision on enrollment timing anticipated in the second half of 2017. The licensor alleged a material breach over development efforts; Galena disputed the claim. NeuVax investigator-sponsored trials continued, with DSMBs recommending continuation and reporting no safety concerns or futility at the reviews described. These findings are not proof of efficacy. GALE-301/302 had completed early-stage trials.
- Government and securities matters: Galena reported an oral agreement in principle with the USAO New Jersey and DOJ for a non-criminal resolution and approximately $7.5 million civil payment, plus interest. The definitive terms and potential additional agency claims remained unresolved. The SEC issued a cease-and-desist order on April 10, 2017; Galena reported $200,000 in penalties and an approximately $750,000 indemnification payment, and said the order restricted certain securities-registration exemptions.
- Debt and dilution: Debenture redemptions may require cash or shares, depending on contractual conditions and waivers. The filing estimated up to 45 million additional shares could be issued under the debenture after May 1, 2017 if shares were issued at the stated $0.35 minimum payment price. Warrants and equity financings also pose dilution risk.
- Listing and controls: Nasdaq notified Galena that its share price was below the $1 minimum bid requirement; the initial compliance deadline was September 20, 2017. Management concluded disclosure controls and procedures were ineffective at March 31, citing late Form 8-K filings. Internal control over financial reporting was assessed as effective.
- Other legal exposure: The filing describes shareholder securities and derivative actions, a Delaware shareholder action, a books-and-records demand, and other proceedings. Outcomes and related costs were uncertain. The company also reported litigation seeking insurance recovery.
- Unusual accounting effects: The warrant-liability gain and contingent-consideration remeasurement were noncash. The $7.5 million government settlement accrual was included in discontinued operations. No income-tax benefit or expense was recognized.
Important facts for investors to verify
- Confirm the filing’s issuer and period: the supplied document is Galena Biopharma’s Q1 2017 10-Q, not a SELLAS filing.
- Track unrestricted versus restricted cash, cash burn, and the timing and availability of new financing; restricted cash was tied to debenture terms.
- Review the executed government settlement, any additional agency claims, and the final cash obligation versus the $7.5 million accrual.
- Monitor debenture redemptions, amendment and waiver conditions, and actual share issuance and dilution relative to the filing’s potential 45 million additional shares.
- Follow the GALE-401 license dispute and Phase 3 readiness, as well as NeuVax trial enrollment and future results; interim safety findings do not establish clinical benefit.
- Check progress on strategic alternatives, Nasdaq bid-price compliance, and remediation of ineffective disclosure controls.